104 results
1. To assess the effects of 3 months neoadjuvant androgen ablation with enzalutamide on the surgicial margin status of men with non-metastasized prostate cancer.2. To properly evaluate the effects of androgen ablation on gene expression, analyses of…
The primary objective for this trial is to assess the local cancer control achieved with FLA in patients with localized low to intermediate risk prostate cancer (Gleason 3+3, 3+4 or Gleason 4+3).Secondary objectives are to determine effectiveness of…
Am2: Primary Objective* To compare the Overall Survival (OS) benefit of docetaxel and prednisone with and without lenalidomide as first-line combination therapy in chemo-naïve metastatic CRPC Secondary Objectives* Progression-Free Survival (PFS), *…
To determine the exposure and clearance of intravenous docetaxel in patients with castration-resistant prostate cancer and non-castration-resistant prostate cancer. All samples will be measured with a validated LC-MS/MS method
The main goal of this phase II study is to investigate whether a focal ablative SBRT boost to the macroscopic tumor is feasible and associated with acceptable toxicity in addition to whole gland prostate SBRT. Based on the present study, a phase III…
The objectives are to determine generic, cancer-generic and prostate cancer-specific HRQOL and costs outside the hospital in CRPC patients during treatment (including best supportive care, docetaxel, cabazitaxel, abiraterone and enzalutamide) in…
The main objective is to evaluate the safety and tolerability of Ad[I/PPT-E1A] as an adjuvant treatment for localised prostate cancer before radical prostatectomy. A secondary objective is to explore the histopathological and immunological effects…
Primary objectives:* To investigate the safety of multiple dosages of E4;* To investigate the efficacy of multiple dosages of E4 on hormone levels related to prostate function.Secondary objectives:* To investigate the pharmacodynamic effects of E4…
The primary objective is to study whether treatment with the mTOR inhibitor Everolimus results in an objectable change in phosphorylation of the selected downstream effectors 4eBP1 and p70S6K in human prostate cancer biopsies. A secondary objective…
-To answer the main question *Can we demonstrate a decreased prevalence of fatigue (i.e. a lower score on the fatigue assessment) in patients in complete remission after successful treatment of a gynaecological malignancy, after treatment of a…
To compare the effect of paclitaxel plus MORAb-003 to paclitaxel plus placebo on progression free survival (PFS) as determined by RECIST in subjects who are in a first platinum-resistant or refractory relapse of ovarian cancer.
Primary objective:- To evaluate the pharmacokinetics, metabolism, and excretion of MDV3100 in plasma, urine, and feces after a single oral 160 mg (100 µCi) dose of 14C-MDV3100.Secondary objective:- To evaluate safety and tolerability of a single…
Primary Objective:To assess the impact of TOOKAD® Soluble VTP on the rate of absence of definite cancer using patients onactive surveillance as a comparison (co-primary objective A).To determine the difference in risk of treatment failure associated…
To improve overall survival of patients with a early-stage high grade uterine leiomyosarcoma.
The objective of this study is to determine how well two different doses of ipilimumab work in patients with prostate cancer who are no longer responding to hormone therapy (castration resistant), and whom have the best radiographic progression-…
To assess the PD, PK and safety of the Zoreline 10.8 mg goserelin subcutaneous (SC) implant.
In this study we therefore investigate the influence of prednisone on docetaxel exposure in metastatic prostate cancer patients.
The primary objective of this study is to further evaluate the safety and effectiveness of the MRI-guided TULSA-PRO device intended to ablate prostate tissue of patients with localized, organ-confined prostate cancer.
Primary:To investigate the safety and tolerability of ascending doses of AZD3514 in patients with metastatic castration resistant prostate cancerSecondary: To assess the pharmacokinetics and preliminary anti-tumour activity of ascending doses of…
Primary objective:To compare the clinical benifit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two chemotherapy regimens, one of…